EZH2 and lymphoma: Some anticancer drugs targeting mutant or wild‐type EZH2, such as GSK126, were used to inhibit EZH2‐mutant lymphoma cells,815 and EPZ‐6438 in a phase I/II clinical trial was designed for treating patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma or advanced solid tumors.812